INGRAM DOUGLAS S 4
4 · Sarepta Therapeutics, Inc. · Filed Dec 9, 2025
Insider Transaction Report
Form 4
INGRAM DOUGLAS S
DirectorPresident & CEO
Transactions
- Award
Common Stock
2025-12-07+50,000→ 440,307 total - Award
Common Stock
2025-12-07+73,001→ 563,308 total - Award
Common Stock
2025-12-07+96,541→ 659,849 total - Award
Common Stock
2025-12-07+269,542→ 929,391 total
Footnotes (5)
- [F1]The Reporting Person was granted performance-contingent restricted stock units ("Performance-Contingent RSUs"), as described in the Company's 2018 Equity Incentive Plan. Each Performance-Contingent RSU represents the right to receive one share of common stock. The Performance-Contingent RSUs are subject to service- and performance-based vesting criteria.
- [F2]The Reporting Person was granted restricted shares, as described in the Company's 2018 Equity Incentive Plan. The restricted shares are subject to service- and performance-based vesting criteria.
- [F3]The Reporting Person was granted Performance Units, as described in the Company's 2018 Equity Incentive Plan. The Performance Units are subject to service- and performance-based vesting criteria.
- [F4]The Reporting Person was granted Performance Shares, as described in the Company's 2018 Equity Incentive Plan. The Performance Shares are subject to service- and performance-based vesting criteria.
- [F5]The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs are subject to service- and performance-based vesting criteria.